Skip to Main Content

WASHINGTON — Donald Trump is unorthodox, to say the least, when it comes to his opinions about the drug industry.

The GOP has historically been a staunch ally for drug companies. But during and after the campaign, the Republican president-elect has sworn he would bring down drug costs, flirting with policies that sound more in line with Bernie Sanders than Paul Ryan.


Trump’s ascent is now generating whispers at the highest levels of industry about whether the Republican Party will remain a bedrock of support. Is Trump an aberration — or is he a sign of things to come?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!